The pharmaceutical industry is pushing back against Governor Cuomo's prescription drug price control proposal, arguing that it would lead to cuts in research. And they are pointing the finger at insurance companies and companies known as pharmacy benefit managers for the high costs paid by patients. Peter Pitts is a former FDA Associate Commissioner for External Relations and is now President of the Center for Medicine in the Public Interest.
Pharmaceutical Industry Raises Issue with Cuomo's Drug Price Control Proposal
RECENT NEWS
CMS comments on IRA Implementation
Allowing pharmacy benefit managers to continue with business-as-usual makes it impossible to build a health care ecosyste... Read more
With 340B Ruling, Corrupt Hospitals Get What They Deserve
The runaway bureaucratic expansion of 340B must stop, and this court ruling is an important step. ... Read more
Abortion ruling adds to growing GOP discontent with FDA
The battle over the drug mifepristone comes after a tough stretch for the FDA: Controversy around the infant formula shor... Read more